Phase I Dose-Escalation Study of Nimustine in Tumor-Bearing Dogs

Masashi TAKAHASHI; Yuko GOTO-KOSHINO; Kenjiro FUKUSHIMA; Hideyuki KANEMOTO; Ko NAKASHIMA; Yasuhito FUJINO; Koichi OHNO; Yasuyuki ENDO; Hajime TSUJIMOTO

doi:10.1292/jvms.13-0345

Internal Medicine

Phase I Dose-Escalation Study of Nimustine in Tumor-Bearing Dogs

Masashi TAKAHASHI, Yuko GOTO-KOSHINO, Kenjiro FUKUSHIMA, Hideyuki KANEMOTO, Ko NAKASHIMA, Yasuhito FUJINO, Koichi OHNO, Yasuyuki ENDO, Hajime TSUJIMOTO

Author information

Masashi TAKAHASHI
Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1–1–1, Yayoi, Bunkyo-ku, Tokyo 113–8657, Japan
Yuko GOTO-KOSHINO
Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1–1–1, Yayoi, Bunkyo-ku, Tokyo 113–8657, Japan
Kenjiro FUKUSHIMA
Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1–1–1, Yayoi, Bunkyo-ku, Tokyo 113–8657, Japan
Hideyuki KANEMOTO
Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1–1–1, Yayoi, Bunkyo-ku, Tokyo 113–8657, Japan
Ko NAKASHIMA
Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1–1–1, Yayoi, Bunkyo-ku, Tokyo 113–8657, Japan
Yasuhito FUJINO
Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1–1–1, Yayoi, Bunkyo-ku, Tokyo 113–8657, Japan
Koichi OHNO
Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1–1–1, Yayoi, Bunkyo-ku, Tokyo 113–8657, Japan
Yasuyuki ENDO
Laboratory of Small Animal Internal Medicine, Joint Faculty of Veterinary Medicine, Kagoshima University, 1–21–24 Korimoto, Kagoshima, Kagoshima 890–0065, Japan
Hajime TSUJIMOTO
Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1–1–1, Yayoi, Bunkyo-ku, Tokyo 113–8657, Japan

Keywords: ACNU cancer, canine, nitrosourea, phase I

JOURNAL FREE ACCESS

2014 Volume 76 Issue 6 Pages 895-899

DOI https://doi.org/10.1292/jvms.13-0345

Browse “Advance online publication” version

Details

Abstract

Nimustine (ACNU) is an alkylating agent of the nitrosourea and can be an antineoplastic agent in dogs. But, there has been no report on its dose-limiting toxicity (DLT) in dogs. This study was a phase I dose-escalation clinical trial to determine the maximum tolerated dose (MTD) and DLT of ACNU in tumor-bearing dogs. The starting dosage was 25 mg/m², and subsequent dosages were administered in increments of 5 mg/m² in cohort of 3 dogs. Eight dogs were included, the MTD was determined to be 25 mg/m², DLT was neutropenia, and the optimal interval was considered to be 21 days. The data herein provide a basis for the subsequent phase II trial of ACNU in dogs.

Corresponding author

Register with J-STAGE for free!